Comparing Clomiphene Citrate Alone Versus Clomiphene Citrate With Pioglitazone for Ovary Stimulation and Pregnancy in Women with Polycystic Ovary Syndrome

What this Trial Is About

This research aims to evaluate the effects of clomiphene citrate alone versus clomiphene citrate combined with pioglitazone on ovarian stimulation and pregnancy rates in women with polycystic ovarian syndrome PCOS who are experiencing infertility. It is a phase 4, randomized, double-blind trial enrolling women aged 18 to 38 years with specific inclusion criteria related to fertility and ovarian health. Participants will be randomly assigned by a computer system to receive either 30 mg of pioglitazone daily or a placebo starting on day 2 of their menstrual cycle. All participants will also take 150 mg of clomiphene citrate daily from day 3 to day 7 of the cycle. On day 10, a transvaginal ultrasound will assess ovarian follicles, and if criteria are met, an injection of human chorionic gonadotropin hCG will trigger ovulation, followed by intrauterine insemination IUI. During the study, participants will be monitored until the end of their menstrual cycle. If menstruation is delayed by 5 days, a blood test will check for pregnancy. Side effects such as swelling, fluid retention, blurred vision, or weight gain will be recorded. The primary outcome measured is ovarian stimulation rate on day 10, and secondary outcomes include pregnancy rates evaluated five days after the cycle ends.

Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate